IDT Biologika acquires Ridgeway Biologicals Ltd
UK specialist company for autogenous vaccines to be integrated in IDT’s Global Animal Health Vaccine Network
Ridgeway Biologicals Ltd is becoming part of IDT Biologika. Pursuing its globalization strategy IDT Biologika expands its network of companies offering autogenous vaccines for animals, following the acquisition of the Canadian Gallant Custom Laboratories in November 2015. The new acquisition was signed on January 5, with the closing of the deal dated on January 1, 2017.
“As a leading supplier of autogenous vaccines for production animals and aquaculture, Ridgeway Biologicals is an optimal fit to our global activities in autogenous vaccines,” says Andreas Kastenbauer, managing director at IDT Biologika. “Ridgeway will be an integral part of our vaccine services offering bespoke solutions to veterinarians all over the world.”
Ridgeway Biologicals is the leading manufacturer for autogenous vaccines in the U.K., with 25 employees working at its facility in Compton, Berkshire, England. The company’s competence and capabilities are based on its own research & development department with the development of bacterial vaccines. Poultry, pig, ruminant and aquaculture vaccines of Ridgeway Biological are sold within Europe through a strong network and broad co-operations.
“We are excited by the opportunity that IDT brings us to move our services internationally”, says Dr Tim Wallis, Managing Director of Ridgeway. “Currently, antibiotics are used in farm animals in the absence of alternatives to control disease, such as effective vaccines for disease prevention. There is huge pressure to reduce antibiotic usage and autogenous vaccines, formulated to the specific requirements of our customers, should be able to help with this aim.”